WinterGreen Research announces that it has published a new study Surgical Robots: Market Shares, Strategy, and Forecasts, Worldwide, 2015 to 2021. The 2015 study has 553 pages, 216 tables and figures. Worldwide surgical robot markets are poised to achieve significant growth as next generation systems provide a way to improve traditional open surgery and decrease the number of ports needed for minimally invasive surgery.
Intuitive Surgical has market leadership position, advanced technology, an impressive installed base and a well trained group of surgeons able to manage the robots. Patients fare better when the surgery is done by surgical robots. The documentation of improvements in care delivery, the ability to ensure better outcomes from surgery promise that surgical robotics is a strong growth market.
Intuitive Surgical will be difficult to dislodge, its dominant position is based on technological excellence that keeps being improved and competitors have a difficult time catching up, much less improving on the Intuitive Surgical technology. Other leading competitors will emerge and the group of several surgical robotic companies will collectively have enough marketing dollars and enough marketing clout to drive replacement of all open surgery. Robotic surgery is positioned to become the standard of care.
Access Full Report With TOC at:
Intuitive Surgical has achieved market saturation in colorectal surgery in the US, it will work on increasing its presence in other surgical market sectors. The leading robotic surgical companies are poised to grow through acquisition, purchasing smaller companies that have developed as specialized product and gained FDA approval. As detailed in the market research study there are a lot of those in every medical specialty and more to come.
The surgical robot market is characterized enormous variety and innovation.
Snake robots are wonderfully interesting surgical robots. Medrobotics offers a highly articulated multilinked robot. It enables minimally-invasive procedures to replace open surgical procedures. It works for many parts of the anatomy. It works in places in the body that are difficult or previously impossible to reach. The robot-assist platform includes on-board visualization. and contains multiple open device channels to accept a variety of third party surgical and interventional instruments. The robot enables physicians to operate through non-linear circuitous paths, self-supported, and through a single-site access into the body.
The maneuverability of the robot is gained from its numerous mechanical linkages with concentric mechanisms. Each mechanism can be placed into a rigid or a limp state. By employing a patented “follow-the-leader” movement strategy with these alternating states, the robot can be directed into any shape through the relative orientations of its linkages.
Initially, a vendor sells and installs the surgical system into new customer accounts. Once systems are sold into customer accounts, the vendor generates recurring revenue as our customers use the system to perform surgery. To do surgeries, the customers need to buy and consume instruments and accessory products. Vendors also generate recurring revenue from system service.
See More Reports of This Category by Radiant Insights:
The ability to deliver such an accurate dose of radiation means that the cancer can be eradicated in patients before the patient is administered a lethal dose of radiation. This prepresents a cure for cancer once it gets working according to the promise of the systems now in place.
In the field of radiation oncology, the Accuray CyberKnife® Robotic Radiosurgery System is universally recognized as the premier radiosurgery system capable of delivering high doses of radiation with submillimeter accuracy anywhere in the body. As validated and proven in numerous peer-reviewed publications, the precision and accuracy of the system combines with continual image guidance and robotic mobility to deliver treatments characterized by high conformality and steep dose gradients.
The newest addition to the CyberKnife product line, the CyberKnife VSI™ System, continues Accuray’s tradition of innovation. Building on a foundation of accuracy and precision in radiosurgery, the CyberKnife VSI System extends these benefits to fractionated high precision radiation therapy with Robotic IMRT™ that can be delivered anywhere in the body. The automated process revolution in surgery and communications is being implemented via robots.
Robots automation of systems is providing significant improvement in the accuracy of surgery and the repeatability of process. According to Susan Eustis, lead author of the study, “Existing open surgery can be replaced in large part by robotic minimally invasive surgery (MIS) during the ofrecast period. Minimally invasive robotic surgery, new robotic radiation treatment, and emerging robotic surgical approaches complement existing surgery techniques. Soon, all surgery will be undertaken with at least come aspects of robotic surgery replacing or complementing open surgery.”
The surgeon performs the procedure while sitting at a console, manipulating the instrument controls and viewing the operation through a vision system. When a surgeon needs to change an instrument the instrument is withdrawn from the surgical field using the controls at the console. This is done many times during an operation.
The companies that get an early foothold in the market have significant strategic advantage. The robotic surgical technique benefits hospitals by reducing the length of patient stays, thereby enabling better cost management. This factor is driving demand for surgery robot systems. Since robotics provide surgeons with a precise, repeatable and controlled ability to perform procedures in tight spaces, they are increasingly in demand.
Intuitive Surgical Accuray
Stryker / Mako Hansen Medical
Medrobotics Freehand 2010
Latest Report by Radiant Insights:
Global Small Cell Lung Cancer Therapeutics Market 2015-2019:
Cancer occurs when, after cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in developed and developing countries. Smoking is considered to be the major cause of small cell lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell carcinoma. It can be further classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer is caused by smoking tobacco, or second hand smoking, or on exposure to asbestos, chromium, arsenic, nickel, soot, or radon. The common symptoms associated with lung cancer are chest pain, incurable cough, blood in sputum, fatigue, loss of appetite, unintentional weight loss, shortness of breath, and wheezing. Small cell lung cancer has a poor prognosis and gets diagnosed only at the late stage of disease progression, and hence, has a high mortality rate. There are no therapies available to cure small cell lung cancer in the market.
TechNavio’s analysts forecast the Global Small Cell Lung Cancer Therapeutics market to grow at a CAGR of 3.60 percent over the period 2014-2019.
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For more information, visit: http://www.radiantinsights.com/
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Email: Send Email
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States